Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer Stage IV
Interventions: DRUG: comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival
Sponsor: Mansoura University